Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells.

PURPOSE: Phase II trial to study the effectiveness of chemotherapy, surgery, radiation therapy, and bone marrow or peripheral stem cell transplantation in treating patients who have primary CNS germ cell tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital Los Angeles
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carboplatin; Cyclophosphamide; Etoposide; Thiotepa

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed newly diagnosed primary CNS germ cell tumor OR

• Serum or cerebrospinal fluid (CSF) elevation of alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (beta-HCG) greater than 50 ng/mL

• Low-risk disease:

• Histologically proven pure germinoma

• Localized, nonmetastatic disease

• Normal CSF

• Normal serum tumor markers

• Intermediate-risk disease:

• Histologically proven germinoma

• Beta-HCG-positive syncytiotrophoblastic giant cell component AND/OR

• CSF elevation of beta-HCG to less than 50 ng/mL

• High-risk disease:

• Histologically proven choriocarcinoma, endodermal sinus tumor, or embryonal carcinoma

• Elevated serum and/or CSF AFP OR

• Elevated serum beta-HCG OR

• Elevated CSF beta-HCG greater than 50 ng/mL OR

• Disseminated disease by MRI and/or CSF cytology

PATIENT CHARACTERISTICS:

Age:

• Any age

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2.0 mg/dL

• Indirect hyperbilirubinemia due to Gilbert's syndrome is allowed

• AST and ALT less than 5 times upper limit of normal

Renal:

• Creatinine clearance greater than 60 mL/min

Cardiovascular:

• Cardiac function normal by echocardiogram

• No myocardial infarction or ischemia in patients over 30 years

• Fractional shortening greater than 30%

Other:

• No unacceptable morbidity of organ systems outside the CNS

• Not pregnant

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy

Endocrine therapy:

• No concurrent corticosteroids administered solely for antiemesis during study chemotherapy

Radiotherapy:

• No prior cranial radiotherapy

Surgery:

• Not specified